AngioDynamics heads into its fiscal first-quarter report with two stories pulling in opposite directions. NanoKnife is accelerating on the back of fresh reimbursement support, while the mechanical thrombectomy business that powered much of last year's growth stalled badly enough to trigger a mid-quarter sales overhaul. The shares have rallied anyway, which means this report is less about whether the company can post a loss in line with forecasts and more about whether the growth engine management rebuilt in the spring is already turning over.

Wall Street expects a loss of 10 cents a share on revenue of about $80.9 million. That would leave the per-share loss flat with the year-ago quarter while lifting sales roughly 6.9%, a pace that sits right around the 5% to 6.5% growth management laid out for fiscal 2027. The Earnings Whisper figure of a 6-cent loss is noticeably better than consensus, suggesting the more engaged crowd expects cost discipline and gross margin gains to show through again, as they did last quarter when the loss narrowed to 7 cents. On the full year, consensus revenue of $325.1 million sits below the low end of the company's $336 million to $341 million target, a sign that analysts are not fully buying the outlook. Oddly, the Street's full-year loss estimate of 8 cents is far narrower than management's guided range of a 24-cent to 29-cent loss, so the two sets of numbers may not be on a strictly comparable basis. Either way, a quarter that tracks toward the guided revenue range would put pressure on skeptical top-line estimates.

The critical test is mechanical thrombectomy. Combined revenue there went from growth above 40% early in fiscal 2026 to a slight decline in the fourth quarter, with AngioVac sliding almost 16%. AlphaVac held up well, rising more than 38%, so the damage was concentrated. Management reorganized the commercial team, installed new leadership and added reps, conceding it had wanted more from the franchise. One quarter is short for a sales reset to bear fruit, but a return to positive growth, or at least a clear stabilization in AngioVac, would validate the fix. Another decline would raise the question of whether the problem is competitive rather than organizational, and would make the 12% to 15% MedTech growth guide look ambitious.

NanoKnife is the counterweight. Fourth-quarter revenue jumped 64.5%, with capital sales more than doubling, as the Category 1 CPT code, a positive Palmetto local coverage decision and a Medicare framework finally took hold for prostate procedures. Capital placements tend to be lumpy, so probe growth is the cleaner read on real procedure adoption. Continued strong disposable volume would show reimbursement is broadening use rather than producing a one-time burst. Commentary on the RELIEF study in BPH and the AlphaReturn pivotal trial will matter for the longer arc, while steady double-digit growth from Arion would help insulate the total.

Margins are the other swing factor. Gross margin reached 54% in the fourth quarter despite roughly $4.8 million of annual tariff costs, a similar burden expected this year, plus disruption from sterilization vendor shutdowns. Holding margins near that level is what the better-than-consensus whisper seems to assume. With about $53.9 million in cash and no debt, the balance sheet is not a worry, though the unresolved CEO search, expected to conclude in the first half of the fiscal year, remains a question hanging over strategy.

The tape tells an interesting story. The stock is up 14.4% since the last report, outpacing the S&P 500 by more than 12 points, and at $15.60 trades well above its 200-day average of $12.45 and in the upper part of its post-earnings range, about 4% below the $16.29 high. Yet sentiment has cooled sharply, to barely bullish from moderately bullish a quarter ago. That combination points to a market that has priced in the NanoKnife story but remains unconvinced on thrombectomy. If the reorganized sales force can show stabilization while NanoKnife keeps compounding, the step-down in guidance will look conservative. If thrombectomy slips again, the rally will have gotten ahead of the fundamentals.